UroGen Pharma Ltd. share price today

UroGen Pharma Ltd.'s share price was $28.74 at the close on 4 November 2026. It has been moving sideways for 1 week. That is 8.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $17 and $48, and at that close it sat 37% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today UroGen Pharma Ltd. is in stage 1. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 5 weeks running.

Over the last 9.5 years the share price moved +105% while the S&P 500 moved +220%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 2 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

UroGen Pharma Ltd. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

UroGen Pharma Ltd. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

UroGen Pharma Ltd. posted a net loss of $14.4 M in the Jun 2026 quarter. The full FY25 year was a loss of $153 M. That loss is 19.8% of the quarter's revenue. The same quarter a year earlier lost $49.9 M. 12 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

UroGen Pharma Ltd. reported $72.5 M of revenue in the Jun 2026 quarter, +199.2% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 23.0% a year on average. The last full year, FY25, came in at $110 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $189 M.

FY25 revenue was $110 M, +21.4% on the year before.

Recent pace: the last four quarters grew +103.4% on average, against 23.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +100.3%, against +49.0% a year over the last 8 quarters (accelerating).

UroGen Pharma Ltd.'s operating margin was 0.2% in the Jun 2026 quarter, 171.4 percentage points higher than the same quarter a year ago. Across 5 years it has been between −192.1% and −79.2%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +171.4 percentage points on the year while gross margin changed +5.6 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

UroGen Pharma Ltd.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $162 M of cash, against −$153 M of profit. After $289 K of spending on assets, free cash was −$163 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

UroGen Pharma Ltd. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $778 K on assets over the last 3 years. Averaged over those years that is 0.2% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $778 K over the last 3 years.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

UroGen Pharma Ltd. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values UroGen Pharma Ltd. at 12.8× its FY25 revenue of $110 M. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

UroGen Pharma Ltd.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

UroGen Pharma Ltd. earned a ROE of 146% in FY25. That is up from a low of −1,317% in FY21. Its return on capital used (ROIC) is 61.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

It comes from a −139.8% net margin and 0.55× asset turnover (sales divided by assets).

Why the return is what it is (FY25): a −139.8% net margin × 0.55× asset turnover × −1.90× leverage (assets divided by equity) ≈ 146.1% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: −49.4% − 12.2% = −61.6 percentage points. The 12.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

UroGen Pharma Ltd.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 0.18 in FY21 to −1.23 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

12.9% of UroGen Pharma Ltd.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For UroGen Pharma Ltd., the Z-score is −3.23. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of −3.23 is inside the danger zone, so the balance sheet is a real risk.

There is no score against its industry: UroGen Pharma Ltd. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

UroGen Pharma Ltd. is the 100th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Immunocore Holdings plc, Taysha Gene Therapies, Inc. and AnaptysBio, Inc. Just below it: Ascentage Pharma Group International, Nektar Therapeutics and Inhibrx Biosciences, Inc.

Biotechnology companies close in size

97. Immunocore Holdings plc $1.5 billion
98. Taysha Gene Therapies, Inc. $1.4 billion
99. AnaptysBio, Inc. $1.4 billion
100. UroGen Pharma Ltd. $1.4 billion
101. Ascentage Pharma Group International $1.3 billion
102. Nektar Therapeutics $1.3 billion
103. Inhibrx Biosciences, Inc. $1.3 billion

All 211 Biotechnology companies, largest first

Companies close in size in other industries

2226. Upbound Group, Inc. $1.4 billion · Software - Application
2227. Nutex Health Inc. $1.4 billion · Medical Care Facilities
2228. UroGen Pharma Ltd. $1.4 billion
2229. Bandwidth Inc. $1.4 billion · Software - Infrastructure
2230. Sweetgreen, Inc. $1.4 billion · Restaurants

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.